Posts

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

on

Q32 Bio Prices $200 Million Public Offering of Common Stock and Pre-Funded Warrants

on

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering – June 24, 2026

on

Definium Therapeutics Prices $700 Million Upsized Public Offering

on

uniQure Announces Pricing of Upsized $225 Million Public Offering: Details and Highlights

on

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

on

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

on

Treeline to go public via reverse merger with Standard BioTools

on

Assembly Biosciences Completes $115 Million Stock and Warrant Offering With Full Underwriters Option Exercise

on

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

on

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

on

Trevi Therapeutics Raises $150M in Public Offering to Fund Haduvio Development

on

INOVIO Announces Proposed Public Offering - December 2024

on

Public Perceptions and Economic Implications of MAHA in 2025 Research

on

CytomX Therapeutics Announces $250 Million Public Offering of Common Stock and Pre-Funded Warrants

on

Dianthus Therapeutics Announces Proposed $400 Million Underwritten Public Offering (Upsized from Initial Plans)

on

Palvella Therapeutics Announces Pricing of Upsized Public Offering

on

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

on

Erasca, Corvus, and BioAge Target $500M+ Offerings Amid Biotech Fundraising Surge

on

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

on